Our results, however, disagree with the observational analysis of Patorno et al.,21 who reported no significant difference in the risk of a composite CV outcome (MI, unstable angina, stroke, or coronary revascularization) between users of GLP-1 RAs and DPP-4 inhibitors. The gene discussed is DPP4; the disease is angina unstable.